Table 2.
Rates of medication coverage for patients with diabetes, for the first quarter of each year, EMR cohort
| Drug | 2010Q1 | 2011Q1 | 2012Q1 | 2013Q1 | 2014Q1 | 2015Q1 | 2016Q1 |
|---|---|---|---|---|---|---|---|
| STATIN | 62.87% | 64.71% | 64.26% | 64.82% | 63.97% | 64.01% | 65.12% |
| ACE INHIBITORS | 43.24% | 43.02% | 41.33% | 39.86% | 38.72% | 37.97% | 37.48% |
| ARB INHIBITORS | 21.07% | 21.43% | 22.25% | 22.23% | 22.62% | 22.43% | 22.87% |
| ACE or ARB | 63.40% | 63.93% | 63.10% | 61.80% | 61.20% | 60.34% | 60.36% |
| ANTIPLATELETS* | 9.39% | 8.84% | 8.48% | 7.83% | 7.39% | 6.58% | 6.49% |
| PPI | 21.85% | 23.25% | 23.79% | 24.83% | 25.36% | 27.32% | 27.65% |
*patients with a history of myocardial infarct were excluded
ACEi: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blockers; PPI: proton pump inhibitor